Orion Porfolio Solutions LLC Has $11.14 Million Stock Position in Gilead Sciences, Inc. $GILD

Orion Porfolio Solutions LLC grew its stake in Gilead Sciences, Inc. (NASDAQ:GILD) by 9.7% during the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 100,321 shares of the biopharmaceutical company’s stock after purchasing an additional 8,843 shares during the period. Orion Porfolio Solutions LLC’s holdings in Gilead Sciences were worth $11,136,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds and other institutional investors have also modified their holdings of the stock. Corundum Trust Company INC bought a new stake in Gilead Sciences in the third quarter valued at $26,000. Howard Hughes Medical Institute acquired a new stake in shares of Gilead Sciences in the 2nd quarter valued at $30,000. MTM Investment Management LLC grew its holdings in shares of Gilead Sciences by 176.0% in the 3rd quarter. MTM Investment Management LLC now owns 276 shares of the biopharmaceutical company’s stock worth $31,000 after purchasing an additional 176 shares during the last quarter. Kilter Group LLC acquired a new stake in shares of Gilead Sciences during the 2nd quarter worth about $33,000. Finally, Millstone Evans Group LLC increased its position in shares of Gilead Sciences by 58.7% during the 3rd quarter. Millstone Evans Group LLC now owns 319 shares of the biopharmaceutical company’s stock worth $35,000 after purchasing an additional 118 shares in the last quarter. Institutional investors own 83.67% of the company’s stock.

Gilead Sciences Stock Down 2.1%

Shares of GILD opened at $145.14 on Friday. The firm has a market capitalization of $180.18 billion, a price-to-earnings ratio of 21.44, a PEG ratio of 1.94 and a beta of 0.37. The company has a debt-to-equity ratio of 0.98, a quick ratio of 1.40 and a current ratio of 1.55. The business’s fifty day moving average price is $137.91 and its two-hundred day moving average price is $125.56. Gilead Sciences, Inc. has a 52 week low of $93.37 and a 52 week high of $157.29.

Gilead Sciences (NASDAQ:GILD) last released its earnings results on Tuesday, February 10th. The biopharmaceutical company reported $1.86 earnings per share for the quarter, topping analysts’ consensus estimates of $1.83 by $0.03. The company had revenue of $7.93 billion during the quarter, compared to the consensus estimate of $7.68 billion. Gilead Sciences had a return on equity of 49.46% and a net margin of 28.90%.The firm’s quarterly revenue was up 4.7% on a year-over-year basis. During the same quarter in the previous year, the company posted $1.90 earnings per share. Gilead Sciences has set its FY 2026 guidance at 8.450-8.850 EPS. On average, analysts predict that Gilead Sciences, Inc. will post 7.95 earnings per share for the current year.

Gilead Sciences Increases Dividend

The firm also recently announced a quarterly dividend, which will be paid on Monday, March 30th. Shareholders of record on Friday, March 13th will be given a dividend of $0.82 per share. This represents a $3.28 dividend on an annualized basis and a yield of 2.3%. The ex-dividend date is Friday, March 13th. This is a boost from Gilead Sciences’s previous quarterly dividend of $0.79. Gilead Sciences’s dividend payout ratio is currently 46.68%.

Insider Buying and Selling at Gilead Sciences

In other news, CFO Andrew D. Dickinson sold 3,000 shares of Gilead Sciences stock in a transaction that occurred on Tuesday, February 17th. The shares were sold at an average price of $154.43, for a total transaction of $463,290.00. Following the completion of the sale, the chief financial officer owned 167,779 shares in the company, valued at $25,910,110.97. The trade was a 1.76% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, insider Johanna Mercier sold 28,000 shares of the stock in a transaction that occurred on Tuesday, February 17th. The shares were sold at an average price of $154.44, for a total transaction of $4,324,320.00. Following the completion of the transaction, the insider owned 120,288 shares in the company, valued at $18,577,278.72. This represents a 18.88% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders sold a total of 309,280 shares of company stock worth $43,935,470 over the last quarter. Company insiders own 0.27% of the company’s stock.

Analyst Ratings Changes

GILD has been the topic of a number of recent analyst reports. Morgan Stanley boosted their price target on shares of Gilead Sciences from $150.00 to $171.00 and gave the company an “overweight” rating in a research report on Wednesday, February 11th. Daiwa Securities Group lifted their target price on shares of Gilead Sciences from $129.00 to $161.00 and gave the company an “outperform” rating in a research note on Wednesday, February 25th. Needham & Company LLC restated a “buy” rating and set a $170.00 price target on shares of Gilead Sciences in a research report on Monday, February 23rd. UBS Group raised their price target on Gilead Sciences from $145.00 to $155.00 and gave the company a “buy” rating in a report on Monday, January 26th. Finally, Sanford C. Bernstein reiterated an “outperform” rating and issued a $160.00 price objective on shares of Gilead Sciences in a research report on Wednesday, February 11th. Twenty-three equities research analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $156.72.

Gilead Sciences Profile

Gilead Sciences, Inc, founded in 1987 and headquartered in Foster City, California, is a biopharmaceutical company focused on the discovery, development and commercialization of medicines in areas of high unmet medical need. The company initially built its reputation in antiviral therapies and has since expanded into oncology, cell therapy and inflammatory diseases. Gilead operates a global research and commercial organization, conducting clinical development and selling medicines in markets around the world.

Gilead’s product portfolio is anchored by antiviral therapies for HIV and viral hepatitis.